2017-2014 Press Releases
2017
July 6, 2017
Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific Officer
May 10, 2017
Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Genome Editing Patent in Europe
May 2, 2017
Caribou Biosciences Announces Grant of a Key CRISPR-Cas9 Patent in the U.S.
2016
October 25, 2016
The Jackson Laboratory and Caribou Biosciences Announce CRISPR-Cas9 License Agreement
September 26, 2016
Caribou Biosciences’ President and CEO Rachel Haurwitz Named to Fortune’s 2016 “40 under 40” List of Most Influential Young People in Business
August 30, 2016
Caribou Biosciences Appoints Vonnie Estes as Group Leader, Agricultural and Industrial Biotechnology
August 18, 2016
Caribou Biosciences Develops New Method to Profile CRISPR-Cas9 Gene Editing Outcomes
May 16, 2016
Caribou Biosciences Raises $30 Million in Series B Funding
February 23, 2016
Caribou Biosciences and Integrated DNA Technologies (IDT) Announce Non-Exclusive License Agreement for CRISPR-Cas9 Reagents
2015
October 8, 2015
Caribou Biosciences and DuPont announce strategic alliance
April 2, 2015
Caribou Biosciences Raises $11 Million in Series A Funding
January 15, 2015
Caribou Biosciences Announces Presentation of New Research Highlighting Progress of its CRISPR-Cas9 Genome Editing Platform
January 7, 2015
Caribou Biosciences Announces New Research Collaboration and Equity Investment Agreements with Novartis
2014
November 18, 2014
Caribou Biosciences Announces Co-Founding of Intellia Therapeutics